Remo CRO

News

Stem cell transplant slows down MS progression

01.19 2019.

Clinical trial compares stem cell transplantation with existing disease-modifying therapies and finds that the former is more effective at slowing down MS. Details

New England Journal of Medicine Publishes Positive Results of the Pivotal Trial of Cablivi (caplacizumab) for Rare Blood Clotting Disorder

01.16 2019.

PARIS, Jan. 9, 2019 /PRNewswire/ — The New England Journal of Medicine (NEJM) today published positive results of the Phase 3 trial of Cablivi® (caplacizumab) in adults with acquired thrombotic thrombocytopenic purpura (aTTP). aTTP is a rare,… Details

Sound Pharmaceuticals Advances Phase 2 Hearing Loss Clinical Trial in Cystic Fibrosis

01.16 2019.

Seattle, WA and Charleston, S.C. — January 14, 2019 — Sound Pharmaceuticals (SPI) is pleased to announce that first-patient-in has been achieved in the STOP Ototoxicity Phase 2 clinical trial. This novel interventional study with SPI-1005 is… Details

Safer sleeping pills keep brain alert to danger

01.15 2019.

Most currently available sleeping pills are so strong that the people who take them could sleep through the sound of a very loud fire alarm. Details

Novartis Investigational Therapy Crizanlizumab (SEG101) Receives FDA Breakthrough Therapy Designation for the Prevention of Vaso-Occlusive Crises in Sickle Cell Disease

01.11 2019.

Basel, January 8, 2019 – Novartis announced today that the US Food and Drug Administration (FDA) has granted crizanlizumab (SEG101) Breakthrough Therapy designation for the prevention of vaso-occlusive crises (VOCs) in patients of all genotypes with… Details

MediciNova Announces Initiation of Enrollment in a Clinical Trial of MN-166 (ibudilast) in Glioblastoma

01.11 2019.

LA JOLLA, Calif., Jan. 08, 2019 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the first… Details